Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6944694 | 0.91 | SMN1; SMN2 (0.56) | HSD17B10GAAL3MBTL1HPGDCYP2C9 | |
| SCHEMBL5085665 | 0.88 | MAPK1 (0.56) | HSD17B10GAAL3MBTL1HPGDCYP2C9 | |
| SCHEMBL6948261 | 0.87 | HSD17B10 (0.55) | HSD17B10GAAL3MBTL1HPGDCYP2C9 | |
| SCHEMBL4445208 | 0.86 | PDE4A (0.54) | HSD17B10HPGDCYP2C9KDM4ETSHR | |
| SCHEMBL19013585 | 0.86 | KDM4E (0.55) | HSD17B10GAAL3MBTL1HPGDCYP2C9 | |
| SCHEMBL8459209 | 0.83 | GAA (0.48) | HSD17B10GAAL3MBTL1HPGDCYP2C9 | |
| SCHEMBL11290176 | 0.83 | KDM4E (0.59) | HSD17B10GAAL3MBTL1HPGDCYP2C9 | |
| SCHEMBL8803669 | 0.82 | MAPK1 (0.51) | HSD17B10L3MBTL1HPGDCYP2C9SMN1; SMN2 | |
| SCHEMBL515910 | 0.82 | GAA (0.53) | HSD17B10GAAL3MBTL1HPGDCYP2C9 | |
| SCHEMBL515834 | 0.82 | KDM4E (0.54) | HSD17B10GAAL3MBTL1HPGDCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193201-B2 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | METAPROTEOMICS, LLC (US) | 2012-06-05 | — | — | US | claimed |
| US-20110172253-A1 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | METAPROTEOMICS, LLC (US) | 2011-07-14 | — | — | US | claimed |
| EP-2338481-A2 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | Metaproteomics, LLC (US) | 2011-06-29 | — | — | EP | claimed |
| US-7914831-B2 | Alpha acids, isoalpha acids, reduced isoalpha acids, tetra-hydroisoalpha acids, hexa-hydroisoalpha acids, beta acids from hops; nontoxic | METAPROTEOMICS, LLC (US) | 2011-03-29 | — | — | US | claimed |
| US-20070185213-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT | 2007-08-09 | — | — | US | claimed |
| EP-1718312-A2 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | Metaproteomics, LLC (US) | 2006-11-08 | — | — | EP | claimed |
| WO-2005084230-A2 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | METAPROTEOMICS, LLC (US) | 2005-09-15 | — | — | WO | claimed |
| US-20050191375-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT | 2005-09-01 | — | — | US | claimed |
| CN-111358787-B | Application of heterocyclic compound in preparation of medicine for treating pneumonia | 四川大学华西医院 | 2021-03-02 | — | — | CN | disclosed |
| CN-111358787-A | Application of heterocyclic compound in preparation of medicine for treating pneumonia | 四川大学华西医院 | 2020-07-03 | — | — | CN | disclosed |
| US-20160128943-A1 | CONTROLLED RELEASE CAFFEINE DOSAGE FORMS | KVK-Tech, Inc. (US) | 2016-05-12 | — | — | US | disclosed |
| EP-1718312-B1 | Pharmaceutical compositions comprising hops extract derivatives and caffeine | METAPROTEOMICS LLC (US) | 2015-03-25 | — | — | EP | disclosed |
| WO-2014197601-A1 | CONTROLLED RELEASE CAFFEINE DOSAGE FORMS | KVK-Tech, Inc. (US) | 2014-12-11 | — | — | WO | disclosed |
| EP-2671584-A2 | Compositions and methods for treating disorders associated with salt or fluid retention | Ironwood Pharmaceuticals, Inc. (US) | 2013-12-11 | — | — | EP | disclosed |
| US-20070185213-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT | 2007-08-09 | — | — | US | disclosed |
| EP-1718312-A2 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | Metaproteomics, LLC (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005084230-A2 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | METAPROTEOMICS, LLC (US) | 2005-09-15 | — | — | WO | disclosed |
| US-20050191375-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT | 2005-09-01 | — | — | US | disclosed |
| EP-1558291-A2 | rAAV-VECTORED RIBOZYME COMPOSITIONS AND METHODS FOR THE TREATMENT OF RETINAL DISEASES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2002088320-A2 | rAAV-VECTORED RIBOZYME COMPOSITIONS AND METHODS FOR THE TREATMENT OF RETINAL DISEASES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC. (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185213-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | HMOX1, HMOX2, HPGDS | HSD17B10 448/4885GAA 4681/4885L3MBTL1 4885/4885 |
| US-20160128943-A1 | CONTROLLED RELEASE CAFFEINE DOSAGE FORMS | SLC18A1, RYR1, SLC6A2 | HSD17B10 1621/4885GAA 1355/4885L3MBTL1 4601/4885 |
| US-20110172253-A1 | SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS USING CURCUMINOIDS OR METHYLXANTHINES | HMOX1, HMOX2, HPGDS | HSD17B10 448/4885GAA 4681/4885L3MBTL1 4885/4885 |
| US-20050191375-A1 | Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines | HMOX1, HMOX2, HPGDS | HSD17B10 448/4885GAA 4681/4885L3MBTL1 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.